Clinical Trials · NCT01240928
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
- Phase
- Phase 1
- Recruitment status
- Withdrawn
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Enrollment
- 0
- Start date
- Not specified
- Locations
- See registry
- Primary endpoint
- Tolerability of MK-2206 given in combination with exemestane +/- goserelin, as measured by maximum tolerated dose (MTD).